PYC Therapeutics Ltd
PYC Therapeutics Advances PKD Program with Phase 1b Multiple Ascending Dose Study Initiation
PYC Therapeutics kicks off Phase 1b MAD for PKD with first patient dosed in PYC-003; data due CY27, paving the way to registrational Phase 2/3 and NDA.
PYC Therapeutics advances groundbreaking treatment for Phelan-McDermid syndrome
PYC Therapeutics (ASX: PYC) has made a breakthrough with its main drug candidate for the potential treatment of neurodevelopmental disorder Phelan-McDermid Syndrome (PMS). New studies by PYC have found it can restore the deficient protein that causes PMS in neurons, the brain cells in which the disorder occurs. The neurons in which these results have […]
Phylogica achieves milestone in drug study aimed at treating childhood blindness
Biotechnology company Phylogica (ASX: PYC) is one step closer to finding a treatment for the leading cause of childhood blindness, achieving a major milestone in its human ‘retina in a dish’ study. The company today reported results from its flagship drug program, in which its proprietary drug delivery technology was used on a 3D model […]
Phylogica’s cell penetrating platform linked to effective administration of drugs for genetic eye disease
A drug delivery platform developed by biotechnology company Phylogica (ASX: PYC) has been shown to be the most effective method of administering anti-sense oligonucleotide (ASO) medications to patients with genetic eye disease. A competitive evaluation test on animal models using Phylogica’s proprietary cell penetrating platform demonstrated the technology could significantly increase the effectiveness of an […]